AI Article Synopsis

  • - The study identifies the significant long-term psychological and quality-of-life impacts on adults diagnosed with Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), beyond the well-documented physical effects.
  • - Through in-depth interviews with 18 adults, two main themes emerged: 'Psychosocial Impacts' and 'Chronicity of Sequelae', highlighting how SJS/TEN changes patients' views on life and affects their overall well-being.
  • - The research concludes that understanding the chronic nature of SJS/TEN is crucial for improving patient care and emphasizes the need for better psychological support and coordinated healthcare pathways after hospital discharge.

Article Abstract

Background: Much has been documented about the physical sequelae of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). While less documented, it is recognized that patients can have long-lasting psychological sequelae. There is a lack of qualitative research on the quality of life (QoL) experiences of adults who have been diagnosed with SJS/TEN.

Objectives: To explore the experiences of adults who had SJS/TEN and how these experiences relate to their QoL.

Methods: Using an interpretative descriptive qualitative study, a purposive sample of 18 adults with SJS/TEN were interviewed using in-depth semi-structured interviews. Data were analysed using content analysis.

Results: Two themes were constructed, each with two categories. Theme 1 (Psychosocial Impacts) included the categories 'The self and others' and 'A changed perspective on life'. Theme 2 (Chronicity of Sequelae) comprised the categories 'Multi-organ involvement' and 'Further consequences of TEN'.

Conclusions: Findings highlighted that SJS/TEN had a significant impact on the different QoL experiences of participants including psychological, physical, social, educational and occupational. Many expressed challenges they faced following discharge from hospital, including gaps in psychological care, navigating disjointed care pathways and lack of coordinated care. If SJS/TEN is viewed as a chronic condition, it is important that researchers and clinicians study the long-term effects of SJS/TEN on people's lives to aid in developing a plan of care to enhance the QoL for this cohort. Psychological and QoL assessments following discharge from hospital require consideration.

Download full-text PDF

Source
http://dx.doi.org/10.1093/bjd/ljae334DOI Listing

Publication Analysis

Top Keywords

stevens-johnson syndrome
8
syndrome sjs
8
sjs toxic
8
toxic epidermal
8
epidermal necrolysis
8
necrolysis ten
8
interpretative descriptive
8
descriptive qualitative
8
qualitative study
8
qol experiences
8

Similar Publications

Introduction: Bortezomib is a reversible proteasome inhibitor that is a first-line chemotherapeutic agent for multiple myeloma. Bortezomib can be administered intravenously or subcutaneously with similar efficacy. Subcutaneous administration has fewer side effects.

View Article and Find Full Text PDF

Purpose: On November 28, 2023, the U.S. FDA issued a Drug Safety Communication, warning that antiseizure medications (ASMs) levetiracetam and clobazam can cause a rare but serious reaction, drug reaction with eosinophilia and systemic symptoms (DRESS).

View Article and Find Full Text PDF

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous disorders characterized by extensive tissue necrosis; they are often accompanied by severe ocular complications (SOC). The regulatory role of microRNAs (miRNAs) in modulating immune responses in SJS/TEN is not fully understood, particularly in relation to chronic SOC. We explored the expression profiles of specific miRNAs and their potential impact on the regulation of key innate immune genes in patients with SJS/TEN with SOC.

View Article and Find Full Text PDF

Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysis.

Invest New Drugs

January 2025

College of Pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China.

The understanding of pembrolizumab-induced Stevens-Johnson syndrome (SJS) /toxic epidermal necrolysis (TEN) primarily derives from case reports, leaving specific clinical features largely unknown. This study aims to investigate the clinical characteristics associated with pembrolizumab-induced SJS/TEN and to encourage the judicious use of pembrolizumab. Retrieve reports on pembrolizumab induced SJS/TEN before September 30, 2024 for retrospective analysis.

View Article and Find Full Text PDF

Stevens-Johnson induced by imiquimod 5% cream: a case report.

Dermatol Reports

November 2024

Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.

Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas, and anogenital warts. Severe systemic side effects associated with imiquimod 5% cream are rare, although a few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated with topical treatment with imiquimod of two superficial basal cell carcinomas.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!